These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 501262)

  • 1. The susceptibility of recently isolates of gram-negative bacteria to amikacin and other aminoglycosides.
    Lexomboon U; Duangmani C; Srimunta C
    J Med Assoc Thai; 1979 Oct; 62(10):544-9. PubMed ID: 501262
    [No Abstract]   [Full Text] [Related]  

  • 2. Susceptibility of current clinical isolates of Pseudomonas aeruginosa and enteric gram-negative bacilli to amikacin and other aminoglycoside antibiotics.
    Dámaso D; Moreno-López M; Martínez-Beltrán J; García-Iglesias MC
    J Infect Dis; 1976 Nov; 134 SUPPL():S394-90. PubMed ID: 825591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The antibacterial activity of amikacin in comparison with four other aminoglycoside antibiotics (proceedings)].
    Schassan HH
    Zentralbl Bakteriol Orig A; 1976 Aug; 235(1-3):320-8. PubMed ID: 983520
    [No Abstract]   [Full Text] [Related]  

  • 4. [Sensitivity of gram-negative germs to Amikacin].
    Redjeb SB; Ennaifer M; Bissardon O; Ben Salah N; Boujnah A
    Tunis Med; 1979; 57(2-3):103-6. PubMed ID: 553336
    [No Abstract]   [Full Text] [Related]  

  • 5. [Phenotypes of resistance to aminosides and sensitivity of amikacin in hospitals].
    Witchitz JL; Golstein FW; Pangon B; Christol D; Acar JF
    Nouv Presse Med; 1979 Oct; 8(42):3417-20. PubMed ID: 537886
    [No Abstract]   [Full Text] [Related]  

  • 6. In vitro susceptibility of gram negative bacteria to amikacin and its comparison with three other aminoglycoside antibiotics.
    Daniel J; Thomas M; Shanmugam J
    Indian J Pathol Microbiol; 1985 Apr; 28(2):115-9. PubMed ID: 3835114
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro activity of isepamicin and other aminoglycosides against clinical isolates of Gram-negative bacteria causing nosocomial bloodstream infections.
    Tsai TY; Chang SC; Hsueh PR; Feng NH; Wang JT
    J Microbiol Immunol Infect; 2007 Dec; 40(6):481-6. PubMed ID: 18087627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Amikacin: a new semisynthetic aminoside antibiotic derivative of kanamycin A. Action spectrum].
    Periti P; Lamanna A; Nicoletti I; Mazzei T; Polito P
    G Ital Chemioter; 1975; 22(1-2):75-86. PubMed ID: 1235358
    [No Abstract]   [Full Text] [Related]  

  • 9. [Comparative evaluation of the activity "in vitro" of 4 aminoglycosides (gentamycin, sisomicin, tobramycin, amikacin)].
    Pinto L; Nobili B; Marchi K; Di Lena C; Esposito L
    Pediatria (Napoli); 1979 Sep; 87(3):399-406. PubMed ID: 550114
    [No Abstract]   [Full Text] [Related]  

  • 10. [Studies on the in vitro antibacterial activities of homemade amikacin on the common bacterial pathogens].
    Wang QN; Jiang YF; Du JZ; Luo MY; Liu YH; Xu ZM
    Yao Xue Xue Bao; 1982 May; 17(5):321-6. PubMed ID: 7180464
    [No Abstract]   [Full Text] [Related]  

  • 11. [Resistance to aminoglycosides among gram - negative bacteria].
    Akalin E; Baykal M
    Mikrobiyol Bul; 1982 Jan; 16(1):1-4. PubMed ID: 7144617
    [No Abstract]   [Full Text] [Related]  

  • 12. [Sensitivity of 1041 strains of bacteria obtained from an intensive care unit with regard to aminoglycosides].
    Beney E; Robert D; Tigaud S; Blanc PL; Vincent P
    Nouv Presse Med; 1982 Nov; 11(46):3396-9. PubMed ID: 7155847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic activity of amikacin with aztreonam against Pseudomonas aeruginosa and other gram-negative organisms.
    Greenberg RN; Bollinger M; Compton J
    Clin Ther; 1986; 8(3):354-8. PubMed ID: 3087621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Study of the microbiological activity in vitro of BB-K-8, a new aminoglycoside antibiotic].
    Ravagnan G; Rasura M; Piccolomini R
    Boll Soc Ital Biol Sper; 1976 Sep; 52(18):1440-6. PubMed ID: 1024552
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical and microbiologic consequences of amikacin use during a 42-month period.
    Berk SL; Alvarez S; Ortega G; Verghese A; Holtsclaw-Berk SA
    Arch Intern Med; 1986 Mar; 146(3):538-41. PubMed ID: 3954526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bactericidal activity and post-antibiotic effect in vitro of dactimicin alone and in combination with other drugs.
    Debbia E; Schito GC; Stefani S; Nicoletti G
    J Chemother; 1989 Jul; 1(4 Suppl):187-8. PubMed ID: 16312361
    [No Abstract]   [Full Text] [Related]  

  • 17. Compiled data on aminoglycoside, foremost netilmicin susceptibility of bacterial strains.
    Juhlin I; Tunevall G
    Scand J Infect Dis Suppl; 1980; Suppl 23():39-44. PubMed ID: 6782657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of the antibacterial effects of gentamycin, tobramycin, dibekacin and amikacin in urinary germs].
    Rothenberger K; Friesen A; Streifinger W; Hofstetter A
    Fortschr Med; 1981 Oct; 99(40):1669-72. PubMed ID: 7298004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Aspects of antibacterial therapy using amikacin].
    Grassi GG; Bucci R; Ferrara A
    G Ital Chemioter; 1976; 23(1):47-54. PubMed ID: 1029696
    [No Abstract]   [Full Text] [Related]  

  • 20. Synthesis and antibacterial activities of 1-N [(S)-omega-amino-2-hydroxyalkyl] kanamycin A derivatives.
    Richardson K; Jevons S; Moore JW; Ross BC; Wright JR
    J Antibiot (Tokyo); 1977 Oct; 30(10):843-6. PubMed ID: 591447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.